Editor-in-chief

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Retrieved on: 
월요일, 2월 26, 2024

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.

Key Points: 
  • Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
  • In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
  • I look forward to helping HeartSciences further advance the field of AI in cardiology.”

Seafood Expo North America/Seafood Processing North America Announces Keynote Address and Conference Sessions Featuring Top Professionals

Retrieved on: 
금요일, 3월 1, 2024

PORTLAND, Maine, March 1, 2024 /PRNewswire-PRWeb/ -- Seafood Expo North America/Seafood Processing North America, produced by Diversified Communications, announces keynote speaker Mark Blyth – William R. Rhodes '57 Professor of International Economics, The Watson Institute for International and Public Affairs at Brown University – and over 30 conference sessions presented by top professionals from across the sector on important topics facing the seafood industry.

Key Points: 
  • PORTLAND, Maine, March 1, 2024 /PRNewswire-PRWeb/ -- Seafood Expo North America/Seafood Processing North America, produced by Diversified Communications, announces keynote speaker Mark Blyth – William R. Rhodes '57 Professor of International Economics, The Watson Institute for International and Public Affairs at Brown University – and over 30 conference sessions presented by top professionals from across the sector on important topics facing the seafood industry.
  • The keynote session will be held on Sunday, March 10th at 11:00am in room 153CB.
  • The conference program, taking place during the three-day expo, will highlight timely topics and bring together a range of professionals to share their unique perspectives and insights.
  • Another session will include professionals from the Seafood Nutrition Partnership, H-E-B and Riverence talking through what drives U.S. consumer behavior and demand for seafood.

The International Myeloma Foundation (IMF) Welcomes Dr. S. Vincent Rajkumar as Chairperson of the Board

Retrieved on: 
금요일, 2월 2, 2024

STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2.

Key Points: 
  • STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2.
  • He has published more than 480 peer-reviewed papers primarily in the field of multiple myeloma and related plasma cell disorders.
  • "I am very grateful that the IMF Board of Directors agreed to approve Dr. Rajkumar as the new IMF Chairperson of the Board when I decided not to seek re-election.
  • "We are thrilled to welcome Dr. S. Vincent Rajkumar as the new Board Chairperson of the International Myeloma Foundation.

Dr. Samuel Lin Continues Partnership With Haute Beauty Network

Retrieved on: 
금요일, 2월 2, 2024

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor's degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year-residency in Otolaryngology-Head and Neck Surgery followed by a three-year-residency in Plastic and Reconstructive Surgery at Northwestern Memorial Hospital. This was followed by a one-year fellowship appointment in Microvascular Reconstructive Surgery at the world-renowned University of Texas M.D. Anderson Cancer Center in Houston, Texas. Throughout the course of his training, Dr. Lin gained state-of-the-art skills in a multitude of reconstructive and cosmetic procedures with his background in Head and Neck Surgery providing him with additional expertise in Plastic and Reconstructive Surgery. He has also been named a Top Influencer in #PlasticSurgery.

Key Points: 
  • Nose Expert from Boston, Dr. Samuel Lin, continues his partnership with Haute Beauty Network, now in his sixth year.
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts.
  • Dr. Lin is board certified by both the American Board of Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.
  • Dr. Lin, his team, and his collaborators regularly publish scientific papers in the literature to further knowledge about plastic surgery and other topics.

Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Retrieved on: 
목요일, 1월 4, 2024

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.
  • I am excited to join the Nexcella team’s efforts to advance NXC-201, a promising CAR-T in relapsed/refractory AL Amyloidosis," commented Dr. Sanchorawala.
  • "Dr. Sanchorawala joining our scientific advisory board further demonstrates our leadership in relapsed/refractory AL Amyloidosis, where NXC-201 is the only CAR-T in development.
  • Dr. Sanchorawala completed residency at Rutgers Health/New Jersey Medical School and her fellowship in hematology/oncology at Boston University Medical Center.

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Retrieved on: 
목요일, 1월 4, 2024

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
  • I am excited to join the Nexcella team’s efforts to advance NXC-201, a promising CAR-T in relapsed/refractory AL Amyloidosis," commented Dr. Sanchorawala.
  • "Dr. Sanchorawala joining our scientific advisory board further demonstrates our leadership in relapsed/refractory AL Amyloidosis, where NXC-201 is the only CAR-T in development.
  • Dr. Sanchorawala completed residency at Rutgers Health/New Jersey Medical School and her fellowship in hematology/oncology at Boston University Medical Center.

Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board

Retrieved on: 
화요일, 12월 5, 2023

Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.

Key Points: 
  • Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.
  • Prior to that, he was Senior Director Clinical Development Oncology at BioNTech SE and Chief Development Officer at 4SC AG.
  • Earlier in his career, Frank Hermann worked in medical affairs and clinical development at Bristol-Myers Squibb, most recently as Associate Medical Director Immuno-Oncology.
  • “We are very pleased that Frank is joining Thermosome as Chief Medical Officer,” said Dr. Pascal Schweizer, co-founder, and CEO/CFO of Thermosome.

Mattamy Homes once again joins ranks of Best Places to Work in Phoenix

Retrieved on: 
월요일, 10월 23, 2023

SCOTTSDALE, AZ, Oct. 23, 2023 /PRNewswire/ - Mattamy Homes has once again been named one of the Best Places to Work by the Phoenix Business Journal.

Key Points: 
  • SCOTTSDALE, AZ, Oct. 23, 2023 /PRNewswire/ - Mattamy Homes has once again been named one of the Best Places to Work by the Phoenix Business Journal.
  • This is the third consecutive year that Mattamy Homes has been recognized.
  • "Being named a Best Place to Work is particularly meaningful as it's a reflection of how our team members feel about working at Mattamy," said Don Barrineau, President of Mattamy's Phoenix Division.
  • Honorees, including Mattamy Homes, will be featured in the Phoenix Business Journal's weekly print and digital edition on Friday, Dec. 15.

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

Retrieved on: 
목요일, 9월 14, 2023

SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board (CAB).

Key Points: 
  • SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board (CAB).
  • "We are excited to have Professor Lu joining our Clinical Advisory Board," said Rita Laeufle, MD, PhD, Phanes' Chief Medical Officer. "
  • Professor Lu is a leading clinician-scientist in the field of lung cancer.
  • He also served on the International Affairs Committee (IAC) of American Clinical Oncology Society (2008-2011) and MCMC Working Group (2008-2016).

Nexcella Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
금요일, 9월 1, 2023

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.

Key Points: 
  • Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • I am thrilled to join the Nexcella Scientific Advisory Board.”
    “We are delighted to be joined by Dr. Lentzsch on the Nexcella Scientific Advisory Board,” stated Ilya Rachman, MD PhD Executive Chairman of Nexcella.